Grufity logoGrufity logo

ONVO

1.51USD-0.01(-0.66%)Market Closed

Organovo Holdings Inc

Market Summary

USD1.51-0.01Market Closed
-0.66%

ONVO Stock Price

RSI Chart

Valuation

Market Cap

15.4M

Price/Earnings

-1.27

Price/Sales

10.11

Price/Cashflow

-1.63

MarketCap/EBT

-155.53

Price/Sales

Profitability

Return on Equity

-43.87%

Return on Assets

-39.71%

Fundamentals

Revenue

Revenue (TTM)

1.5M

Earnings

Earnings (TTM)

-11.9M

Earnings Y/Y

5.25%

Earnings Q/Q

-3.3%

Price Action

52 Week Range

1.485.44
(Low)(High)

Last 7 days

-2.6%

Last 30 days

-15.6%

Last 90 days

-41.2%

Trailing 12 Months

-68.5%

Financial Health

Current Ratio

20.99

Investor Care

Shares Dilution (1Y)

0.09%

Diluted EPS (TTM)

-1.37

Peers (Alternatives to Organovo Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
16.6B
3.3B
6.30% 17.26%
17.56
5
22.05% 63.88%
MID-CAP
6.1B
1.9B
21.61% -51.58%
-8.33
3.16
13.25% 11.39%
5.4B
1.6B
3.67% -3.09%
19.63
3.44
30.66% 87.25%
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.5B
-
-36.22% -66.97%
-4.09
-
-40.64% -32.64%
1.3B
-
33.67% 61.22%
-7.74
-379.9M
- -38.05%
728.9M
60.3M
-15.09% -77.39%
-1.39
13.26
17.51% -38.87%
553.7M
130.5M
15.66% 116.67%
-7.57
5.03
90.44% 5.49%
431.9M
463.2M
-15.24% -73.45%
5.91
0.94
3.79% -0.40%
112.3M
-
-3.83% -83.97%
-2.78
28.9K
- -201.36%
104.3M
206.9M
86.84% 22.41%
-3.03
0.5
-18.84% 1.68%
15.4M
1.5M
-15.64% -68.48%
-1.27
10.11
- -7.21%

Financials for Organovo Holdings

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q12020Q12019Q42019Q32019Q2
Revenue-31.7%1,5002,1962,8763,3573,070
Cost Of Revenue-300
  S&GA Expenses-9,659
  R&D Expenses-3,320
Net Income--11,448.00
Balance Sheet
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.6%27,91030,54633,29635,09535,881
  Current Assets-9.5%24,35726,90929,53331,17134,303
    Cash Equivalents-14.6%13,30015,56828,67530,30033,791
  Net PPE9.9%758690662652552
Liabilities0.4%2,9042,8923,0873,802-
  Current Liabilities8.3%1,3891,2821,3832,0061,675
Shareholder's Equity-9.6%25,00627,65430,20931,29334,206
  Retained Earnings-1.1%-314,275.00-310,954.00-307,739.00-305,800.00-302,300.00
  Additional Paid-In Capital0.2%339,273338,600337,940337,113336,526
Accumulated Depreciation-1,071----
Shares Outstanding0.0%8,7138,7128,7118,7068,705
Float-58,025----
* denotes actual numbers (not divided by Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-0.3%-9,484.00-9,454.00-8,453.00-9,026.00-7,205.00
  Share Based Compensation9.9%2,7482,5012,2561,7161,334
Cashflow From Investing-0.5%-10,965.00-10,908.00-409.00-467.00-623.00
Cashflow From Financing97.8%-1.00-46.0020520,95824,030
  Buy BacksNaN%000
* denotes actual numbers (not divided by Thousands)

Risks

What is the probability of a big loss on ONVO?

100%


Probability that Organovo Holdings stock will be more than 20% underwater in next one year

100%


Probability that Organovo Holdings stock will be more than 30% underwater in next one year.

99.6%


Probability that Organovo Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ONVO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Organovo Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on ONVO

-28.1%


10-Year Cumulative Returns

-41.9%


7-Year Cumulative Returns

-45.1%


5-Year Cumulative Returns

-46.0%


3-Year Cumulative Returns

What are the long-term rolling returns for ONVO?

FIve years rolling returns for Organovo Holdings.

Which funds bought or sold ONVO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-1,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
-
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
8,000
57,000
-%
2022-11-14
Princeton Global Asset Management LLC
UNCHANGED
-
-
-
-%
2022-11-14
JPMORGAN CHASE & CO
UNCHANGED
-
-
-
-%
2022-11-14
BANK OF AMERICA CORP /DE/
REDUCED
-4.84
-
-
-%
2022-11-14
FIRST MANHATTAN CO
UNCHANGED
-
-
-
-%
2022-11-14
WELLS FARGO & COMPANY/MN
REDUCED
-41.49
-1,000
1,000
-%
2022-11-14
ROYAL BANK OF CANADA
REDUCED
-93.17
-3,000
-
-%

1–10 of 42

Latest Funds Activity

Are funds buying ONVO calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ONVO

Organovo Holdings News

openPR

3D Bioprinting Market Recent Developments and Growth Outlook 2022 to 2030.7 days ago

ONVO Fair Value

Recent SEC filings of Organovo Holdings

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 10, 2022
10-Q
Quarterly Report
Oct 25, 2022
S-8
Employee Benefits Plan
Oct 25, 2022
S-8 POS
Employee Benefits Plan
Oct 25, 2022
S-8 POS
Employee Benefits Plan

Latest Insider Trading transactions for ONVO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-10
Joshi Vaidehi
ACQUIRED
-
-
19,607
-
2022-11-10
Gobel David
ACQUIRED
-
-
19,607
-
2022-11-10
Milhous Alison Tjosvold
ACQUIRED
-
-
19,607
-
2022-11-10
Cohen Douglas Jay
ACQUIRED
-
-
19,607
-
2022-11-10
STERN ADAM K
ACQUIRED
-
-
19,607
-
2022-11-10
Murphy Keith
ACQUIRED
-
-
19,607
Executive Chairman
2021-11-19
Gobel David
SOLD
-766.325
5.285
-145
-
2021-08-17
Cohen Douglas Jay
BOUGHT
6,719.8
6.7198
1,000
-
2021-08-17
Cohen Douglas Jay
BOUGHT
58,838.5
6.7244
8,750
-
2021-08-17
Cohen Douglas Jay
BOUGHT
6,737.9
6.7379
1,000
-

1–10 of 36

Keith Murphy
9
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

ONVO Income Statement

2022-09-30
Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues    
Total Revenues$ 77$ 0$ 77$ 0
Revenue From Contract With Customer Product And Service [Extensible List]us-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMember
Research and development expenses$ 1,231$ 679$ 2,251$ 1,259
Selling, general and administrative expenses2,2002,8284,4194,807
Total costs and expenses3,4313,5076,6706,066
Loss from Operations(3,354)(3,507)(6,593)(6,066)
Other Income (Expense)    
Loss on investment in equity securities(70)0(75)0
Interest income10321344
Other income00025
Total Other Income3325929
Income Tax Expense00(2)0
Net Loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)
Net loss per common share basic$ (0.38)$ (0.40)$ (0.75)$ (0.69)
Net loss per common share diluted$ (0.38)$ (0.40)$ (0.75)$ (0.69)
Weighted average shares used in computing net loss per common share basic8,712,2848,705,3278,711,6308,701,029
Weighted average shares used in computing net loss per common share diluted8,712,2848,705,3278,711,6308,701,029
Comprehensive Loss:    
Net loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)
Comprehensive loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)

ONVO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current Assets  
Cash and cash equivalents$ 13,265$ 28,675
Short-term investments9,9550
Investment in equity securities6180
Prepaid expenses and other current assets519858
Total current assets24,35729,533
Fixed assets, net758662
Restricted cash143143
Operating lease right-of-use assets1,9582,153
Prepaid expenses and other assets, net694805
Total assets27,91033,296
Current Liabilities  
Accounts payable441415
Accrued expenses462489
Operating lease liability, current portion486479
Total current liabilities1,3891,383
Operating lease liability, net of current portion1,5151,704
Total liabilities2,9043,087
Stockholders’ Equity  
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,713,268 and 8,710,627 shares issued and outstanding at September 30, 2022 and March 31, 2022, respectively99
Additional paid-in capital339,273337,940
Accumulated deficit(314,275)(307,739)
Treasury stock, 46 shares at cost(1)(1)
Total stockholders’ equity25,00630,209
Total Liabilities and Stockholders’ Equity$ 27,910$ 33,296